Canada Cancer Diagnostics Market Size & Outlook, 2023-2030
Canada cancer diagnostics market, 2018-2030 (US$M)
Related Markets
Canada cancer diagnostics market highlights
- The Canada cancer diagnostics market generated a revenue of USD 7,342.3 million in 2023 and is expected to reach USD 10,750.1 million by 2030.
- The Canada market is expected to grow at a CAGR of 5.6% from 2024 to 2030.
- In terms of segment, consumables was the largest revenue generating product in 2023.
- Consumables is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer diagnostics market data book summary
| Market revenue in 2023 | USD 7,342.3 million |
| Market revenue in 2030 | USD 10,750.1 million |
| Growth rate | 5.6% (CAGR from 2023 to 2030) |
| Largest segment | Consumables |
| Fastest growing segment | Consumables |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Services, Instruments, Consumables |
| Key market players worldwide | Abbott Laboratories, Roche Holding AG, GE HealthCare Technologies Inc Common Stock, Qiagen NV, Becton Dickinson & Co, Koninklijke Philips NV, Siemens Healthineers AG ADR, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc |
Other key industry trends
- In terms of revenue, Canada accounted for 6.8% of the global cancer diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 10,750.1 million by 2030.
Consumables was the largest segment with a revenue share of 60.01% in 2023. Horizon Databook has segmented the Canada cancer diagnostics market based on services, instruments, consumables covering the revenue growth of each sub-segment from 2018 to 2030.
Canada’s market is expected to grow at a lucrative rate over the forecast period. It follows the U.S. in adopting diagnostic tests, as FDA-approved tests are permitted in the country. In contrast to conventional cancer screening programs, emerging health technologies that use liquid biopsy techniques for the early diagnosis of cancer may present a fresh strategy.
These tests may aid in lowering some of the obstacles related to conventional screening tests and extending the reach of screening beyond specific cancers. Emerging technologies include the Galleri Test (GRAIL) and CancerSEEK (Exact Sciences Corporation), which use NGS, computational algorithms with AI, and molecular analysis of blood samples to detect signs of various types of cancer.
In May 2022, StageZero Life Sciences entered into a collaboration agreement with DiagnoseAtHome to offer a multicancer blood test, Aristotle, to patients in Canada and the U.S. According to the Canadian Journal of Health Technologies, more than 80,000 deaths occur in Canada each year due to cancer, which is a leading cause of death.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Diagnostics Market Scope
Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada cancer diagnostics market size, by product, 2018-2030 (US$M)
Canada Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
